U.S. Software Stock News

NYSE:VZ
NYSE:VZTelecom

US Stock Market Today S&P 500 Futures Slip On Global Manufacturing And Rate Worries

The Morning Bull - US Market Morning Update Monday, Feb, 2 2026 US stock futures are pointing lower this morning, with E-mini S&P 500 contracts down about 0.7% and Nasdaq futures off roughly 1%, as investors react to weaker manufacturing signals and rising borrowing costs abroad. Across Europe, key manufacturing scorecards such as Italy’s and Spain’s PMIs are still below 50, which marks contraction and hints that factories are receiving fewer new orders and facing higher input costs,...
NasdaqGS:GIII
NasdaqGS:GIIILuxury

A Look At G‑III Apparel Group (GIII) Valuation After Dividend Move And Higher Fiscal 2026 Guidance

G-III Apparel Group (GIII) is back on investors’ radar after approving a quarterly dividend of US$0.10 per share and raising its fiscal 2026 earnings guidance following stronger-than-expected third quarter results. See our latest analysis for G-III Apparel Group. The dividend decision and upgraded fiscal 2026 guidance come as the share price trades at US$29.35, with a 9.03% 90 day share price return and a 77.69% three year total shareholder return. This suggests momentum has picked up...
NYSE:AGRO
NYSE:AGROFood

The Bull Case For Adecoagro (AGRO) Could Change Following Upgraded Earnings Outlook And Value Rating Shift

In recent months, Adecoagro has received a Zacks Rank #2 (Buy) as analysts sharply revised full-year earnings estimates higher and highlighted its value rating. What stands out is that Adecoagro’s valuation metrics, including P/E, PEG, P/B, and P/S ratios, compare favorably with its industry even as earnings expectations improve. We’ll now examine how this stronger earnings outlook, combined with favorable valuation ratios, shapes Adecoagro’s broader investment narrative for investors...
NasdaqGM:TRVI
NasdaqGM:TRVIPharmaceuticals

Did JAMA-Published CORAL Data on Nalbuphine ER Just Shift Trevi Therapeutics' (TRVI) Investment Narrative?

Trevi Therapeutics recently reported that key results from its Phase 2b CORAL trial of oral nalbuphine ER for chronic cough in idiopathic pulmonary fibrosis were published in the Journal of the American Medical Association, with safety outcomes broadly consistent with prior studies. The data showed similar discontinuation rates between nalbuphine ER and placebo and fewer serious adverse events in the nalbuphine ER group, underscoring a potentially differentiated safety profile. Next, we’ll...
NYSE:UWMC
NYSE:UWMCDiversified Financial

Does UWM Holdings' (UWMC) CEO Stock Sale Reframe the Market’s View of Management Alignment?

In January 2026, UWM Holdings CEO Mat Ishbia indirectly sold 1,898,622 shares of Class A common stock for about US$11.14 million under a pre-arranged 10b5-1 trading plan, reducing his overall holdings while leaving his direct ownership unchanged. The scale and timing of these insider sales, against a backdrop of weak mortgage loan volumes, have intensified investor focus on UWM’s leadership intentions and longer-term corporate direction. We’ll now examine how Ishbia’s sizable insider sale...